What do systematic reviews say?

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

• Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 2144 participants
  Very low

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

• Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2775 participants
  Low

Diet vs physical activity or standard treatment

• Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 530 participants
  Very low

Diet vs physical activity or standard treatment

• Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 530 participants
  Very low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Summary of findings ‐ Hydroxyurea and phlebotomy showed no clear difference in death during the study (all deaths) compared with transfusion and chelation (low certainty).

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  RR 0.99 [0.06, 15.42]
  2 studies · 254 participants
  Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

The review found no eligible studies for this question.

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Low

Hydroxyurea vs observation

The review found no eligible studies for this question.

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs observation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Hydroxyurea vs observation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Hydroxyurea vs observation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Hydroxyurea vs observation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Hydroxyurea vs observation

The review found no eligible studies for this question.

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs observation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 22 participants
  Very low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

Summary of findings ‐ Hydroxyurea and phlebotomy may leads to higher pain alteration: proportion experiencing serious VOC or… compared with transfusion and chelation (low certainty).

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  RR 3.37 [1.59, 7.11]
  2 studies · 254 participants
  Low

Summary of findings ‐ Hydroxyurea and phlebotomy vs transfusion and chelation

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 254 participants
  Moderate

Heparin prophylaxis vs no treatment/placebo

The review found no eligible studies for this question.

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

LMWH prophylaxis vs UFH

It is very uncertain whether antenatal (± postnatal) prophylaxis: LMWH changes adverse effects sufficient to stop treatment compared with UFH (very low certainty).

• Venous thromboembolism prophylaxis for women at risk during pregnancy and the early postnatal period 2021 · Cochrane Headline outcomes only
  RR 0.07 [0.01, 0.54]
  2 studies · 226 participants
  Very low